Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. (Q43872744)

27 November 2017

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. (English)

1 reference

27 November 2017

0 references

1 reference

1 reference

1 reference

2

1 reference

27 November 2017

Gauduin MC

1

1 reference

27 November 2017

Weir R

3

1 reference

27 November 2017

Barbas CF

4

1 reference

27 November 2017

Burton DR

5

1 reference

27 November 2017

Koup RA

6

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

27 November 2017

1 reference

27 November 2017

3

1 reference

27 November 2017

1389-1393

1 reference

27 November 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/nm1297-1389

27 November 2017

0 references

cites work

Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

Quantitation of human immunodeficiency virus type 1 in the blood of infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

HIV vaccines: where we are and where we are going

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Human immunodeficiency virus infection of human-PBL-SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Vaccination of chimpanzees against HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Jitters jeopardize AIDS vaccine trials

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Defining antibody protection against HIV-1 transmission in Hu-PBL-SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Immunologic and pharmacologic concepts of monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

A vaccine for HIV type 1: the antibody perspective

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Quantitative assessment of human immunodeficiency virus type 1 replication in human xenografts of acutely infected Hu-PBL-SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FNM1297-1389

7 January 2021

Identifiers

DOI

10.1038/NM1297-1389

1 reference

27 November 2017

1 reference